Sunitinib for the management of advanced renal cell carcinoma

References

• Escudier B, Kataja V, on behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20, iv81–iv82 (2009).
   Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18, 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Levi F, Ferlay J, Galeone C et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int.101, 949–958 (2008).
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. SUTENT, summary of product characteristics. (2009).
   Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Ravaud A, Oudard S et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Presented at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12–16 September 2008 (Abstract 72O).
   Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27, 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier BJ, Bellmunt J, Negrier S et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastaric renal cell carcinoma (mRCC). J. Clin. Oncol.27 (2009) (Abstract 5020).
   Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Kay A, Motzer RJ, Figlin RA et al. Updated data from a Phase 3 trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Eur. Urol.8(Suppl.), 185 (2009).
   Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg J et al. Bevacizumab plus interferon-α versus interferon-α monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J. Clin. Oncol.27 (2009) (Abstract LBA5019).
   Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. (2010) (Epub ahead of print).
   Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab.91, 4070–4076 (2006).
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther.2, 471–478 (2003).
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control14, 285–294 (2007).
   PubMedGoogle Scholar
• Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell3, 439–443 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood101, 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis20, 757–766 (2003).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362, 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov.6, 734–745 (2007).
   PubMed Web of Science ®Google Scholar
• Barrios CH, Hernandez-Barajas D, Brown MP et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Presented at the 8th International Kidney Cancer Symposium, Chicago, USA, 25–26 September 2009.
   Google Scholar
• Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27, 4068–4075 (2009).
   PubMed Web of Science ®Google Scholar
• Khosravan R, Toh M, LaFargue J, Ni G, Bello C. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J. Clin. Oncol.26 (2008) (Abstract 2578).
   PubMedGoogle Scholar
• Houk B, Bello C, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res.5, 2497–2506 (2009).
   Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol.178, 1883–1887 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, USA, 1–5 June 2007 (Abstract 5024).
   Google Scholar
• Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev.CD001425 (2005).
   Google Scholar
• Cella D, Li JZ, Cappelleri JC et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J. Clin. Oncol.26, 3763–3769 (2008).
   PubMed Web of Science ®Google Scholar
• Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol.26, 3995–4000 (2008).
   PubMed Web of Science ®Google Scholar
• Benedict Á, Figlin RA, Charbonneau C. Economic evaluation of sunitinib vs. sorafenib and bevacizumab plus interferon-alfa among all patients and sunitinib vs. temsirolimus in poor-risk patients as first-line therapy of metastatic renal cell carcinoma in the US. Presented at the 8th International Kidney Cancer Symposium. Chicago, USA 25–26 September 2009.
   Google Scholar
• Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol.10, 757–763 (2009).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26, 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a Phase II study. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 30 May–3 June 2008 (Abstract 5112).
   Google Scholar
• Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 1432–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia JA, Cooney MM et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res.15, 6277–6283 (2009).
   PubMed Web of Science ®Google Scholar
• Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer7, 24–27 (2009).
   PubMed Web of Science ®Google Scholar
• Kroog GS, Feldman DR, Kondagunta GV, et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, (2009) (Abstract 5037).
   Google Scholar
• Amin C, Wallen E, Pruthi RS et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology72, 864–868 (2008).
   PubMed Web of Science ®Google Scholar
• Ansari J, Doherty A, McCafferty I et al. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin. Genitourin. Cancer7, E39–E41 (2009).
   PubMedGoogle Scholar
• Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat. Rev. Urol.6, 338–343 (2009).
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Suardi N, Jeldres C et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol.53, 845–848 (2008).
   PubMed Web of Science ®Google Scholar
• Robert G, Gabbay G, Bram R et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur. Urol.55, 1477–1480 (2009).
   PubMed Web of Science ®Google Scholar
• Shuch B, Riggs SB, LaRochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int.102, 692–696 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol.181, 518–523 (2009).
   PubMed Web of Science ®Google Scholar
• Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol.53, 917–930 (2008).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist13, 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann. Oncol.20(Suppl. 1), i7–i12 (2009).
   Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can. Urol. Assoc. J.1, S41–S54 (2007).
   Web of Science ®Google Scholar
• Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med.145, 660–664 (2006).
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Porta C, Szczylik C, Bracarda S et al. Short and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J. Clin. Oncol.26 (2008) (Abstract 5114).
   PubMedGoogle Scholar